PT1660095E - Inibidores tricíclicos de parp - Google Patents
Inibidores tricíclicos de parp Download PDFInfo
- Publication number
- PT1660095E PT1660095E PT04743516T PT04743516T PT1660095E PT 1660095 E PT1660095 E PT 1660095E PT 04743516 T PT04743516 T PT 04743516T PT 04743516 T PT04743516 T PT 04743516T PT 1660095 E PT1660095 E PT 1660095E
- Authority
- PT
- Portugal
- Prior art keywords
- parp inhibitors
- tricyclic
- lactam
- relates
- tricyclic parp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317466.1A GB0317466D0 (en) | 2003-07-25 | 2003-07-25 | Use |
| GB0408524A GB0408524D0 (en) | 2004-04-16 | 2004-04-16 | Use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1660095E true PT1660095E (pt) | 2010-04-19 |
Family
ID=34117642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04743516T PT1660095E (pt) | 2003-07-25 | 2004-07-23 | Inibidores tricíclicos de parp |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7531530B2 (pt) |
| EP (1) | EP1660095B1 (pt) |
| JP (2) | JP5466814B2 (pt) |
| KR (1) | KR101138471B1 (pt) |
| AT (1) | ATE454893T1 (pt) |
| AU (1) | AU2004261462B2 (pt) |
| BR (1) | BRPI0412899B1 (pt) |
| CA (1) | CA2533332C (pt) |
| CY (1) | CY1110335T1 (pt) |
| DE (1) | DE602004025123D1 (pt) |
| DK (1) | DK1660095T3 (pt) |
| ES (1) | ES2339663T3 (pt) |
| HK (1) | HK1084602A1 (pt) |
| IL (1) | IL173336A (pt) |
| MX (1) | MXPA06000993A (pt) |
| NO (1) | NO334610B1 (pt) |
| NZ (1) | NZ544989A (pt) |
| PL (1) | PL1660095T3 (pt) |
| PT (1) | PT1660095E (pt) |
| RU (1) | RU2404183C2 (pt) |
| SI (1) | SI1660095T1 (pt) |
| WO (1) | WO2005012305A2 (pt) |
| ZA (1) | ZA200600679B (pt) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030020488A (ko) * | 2001-08-29 | 2003-03-10 | 강정훈 | 대나무 추출물을 유효성분으로 하는 화상치료용 조성물 |
| WO2004087713A1 (en) * | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| EP2305221B1 (en) * | 2003-12-01 | 2015-05-20 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for treatment of cancer |
| KR20070046183A (ko) * | 2004-09-22 | 2007-05-02 | 화이자 인코포레이티드 | 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는치료 배합물 |
| ATE551345T1 (de) * | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
| MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
| BRPI0613783A2 (pt) | 2005-07-18 | 2011-02-01 | Bipar Sciences Inc | tratamento de cáncer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| AU2007292306A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| DK2209375T3 (da) | 2007-10-03 | 2014-10-06 | Eisai Inc | Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf |
| CN101918003A (zh) * | 2007-11-12 | 2010-12-15 | 彼帕科学公司 | 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌 |
| AU2008321128A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| MX2010008572A (es) * | 2008-02-04 | 2010-11-30 | Bipar Sciences Inc | Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa. |
| GB0804755D0 (en) * | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| EP3150610B1 (en) | 2010-02-12 | 2019-07-31 | Pfizer Inc | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| DK3327148T3 (da) | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
| AU2011293635B2 (en) | 2010-08-24 | 2015-11-26 | Children's Medical Center Corporation | Methods for predicting anti-cancer response |
| JP5699223B2 (ja) | 2010-12-02 | 2015-04-08 | シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド | 複素環誘導体、その合成法および医療用途 |
| CA2833914A1 (en) * | 2011-05-10 | 2012-11-15 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
| WO2012174378A2 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| KR102164964B1 (ko) | 2011-07-22 | 2020-10-14 | 페이실렉스 파마슈티컬스 인코포레이티드 | 암의 합성치사 및 치료 |
| EP3660161A1 (en) | 2011-12-21 | 2020-06-03 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2687024T3 (es) | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| NZ630278A (en) | 2012-06-07 | 2017-02-24 | Inst Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2892344A1 (de) * | 2012-09-05 | 2015-07-15 | Bayer CropScience AG | Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| US10308986B2 (en) | 2013-03-14 | 2019-06-04 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| EP3693475A1 (en) | 2013-04-05 | 2020-08-12 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| ES2909899T3 (es) | 2013-12-09 | 2022-05-10 | Inst Curie | Métodos para detectar inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
| WO2016028689A1 (en) | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | High dosage strength tablets of rucaparib |
| KR20160116831A (ko) | 2015-03-31 | 2016-10-10 | (주)아모레퍼시픽 | 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물 |
| EP3325662B1 (en) | 2015-07-17 | 2023-08-30 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
| DK3594343T3 (da) | 2015-07-23 | 2021-06-28 | Inst Curie | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10857156B2 (en) | 2015-11-20 | 2020-12-08 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CA3019132A1 (en) | 2016-04-01 | 2017-10-05 | NOHMs Technologies, Inc. | Modified ionic liquids containing phosphorus |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| EP3534957A1 (en) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| WO2018165615A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| US20200129476A1 (en) | 2017-04-28 | 2020-04-30 | Akribes Biomedical Gmbh | PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing |
| EP3656010A4 (en) | 2017-07-17 | 2021-08-11 | Nohms Technologies, Inc. | ELECTROLYTES CONTAINING PHOSPHORUS |
| PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
| CN112334133A (zh) | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
| WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
| WO2021018298A1 (zh) * | 2019-08-01 | 2021-02-04 | 南京明德新药研发有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115485271A (zh) | 2020-04-28 | 2022-12-16 | 理森制药股份公司 | 用作聚(adp-核糖)聚合酶（parp）抑制剂的新型化合物 |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CN117321044A (zh) | 2021-04-08 | 2023-12-29 | 理森制药股份公司 | 聚(adp-核糖)聚合酶抑制剂 |
| EP4141127A1 (en) | 2021-08-30 | 2023-03-01 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287338B6 (sk) * | 1999-01-11 | 2010-07-07 | Agouron Pharmaceuticals, Inc. | Tricyklická zlúčenina, jej použitie a farmaceutická kompozícia s jej obsahom |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| EP2305221B1 (en) | 2003-12-01 | 2015-05-20 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for treatment of cancer |
| KR20070046183A (ko) | 2004-09-22 | 2007-05-02 | 화이자 인코포레이티드 | 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는치료 배합물 |
-
2004
- 2004-07-23 US US10/565,308 patent/US7531530B2/en active Active
- 2004-07-23 RU RU2006105652/04A patent/RU2404183C2/ru active
- 2004-07-23 JP JP2006521648A patent/JP5466814B2/ja active Active
- 2004-07-23 US US10/898,653 patent/US7351701B2/en active Active
- 2004-07-23 NZ NZ544989A patent/NZ544989A/en unknown
- 2004-07-23 WO PCT/GB2004/003183 patent/WO2005012305A2/en active Application Filing
- 2004-07-23 PT PT04743516T patent/PT1660095E/pt unknown
- 2004-07-23 BR BRPI0412899-0A patent/BRPI0412899B1/pt not_active IP Right Cessation
- 2004-07-23 AU AU2004261462A patent/AU2004261462B2/en active Active
- 2004-07-23 AT AT04743516T patent/ATE454893T1/de active
- 2004-07-23 DE DE602004025123T patent/DE602004025123D1/de active Active
- 2004-07-23 DK DK04743516.9T patent/DK1660095T3/da active
- 2004-07-23 KR KR1020067001725A patent/KR101138471B1/ko active IP Right Grant
- 2004-07-23 PL PL04743516T patent/PL1660095T3/pl unknown
- 2004-07-23 ES ES04743516T patent/ES2339663T3/es active Active
- 2004-07-23 SI SI200431370T patent/SI1660095T1/sl unknown
- 2004-07-23 MX MXPA06000993A patent/MXPA06000993A/es active IP Right Grant
- 2004-07-23 EP EP04743516A patent/EP1660095B1/en active Active
- 2004-07-23 CA CA2533332A patent/CA2533332C/en active Active
-
2006
- 2006-01-24 IL IL173336A patent/IL173336A/en active IP Right Grant
- 2006-01-24 ZA ZA2006/00679A patent/ZA200600679B/en unknown
- 2006-02-24 NO NO20060928A patent/NO334610B1/no unknown
- 2006-06-19 HK HK06106961.6A patent/HK1084602A1/xx unknown
-
2010
- 2010-03-31 CY CY20101100309T patent/CY1110335T1/el unknown
-
2011
- 2011-11-29 JP JP2011260401A patent/JP5580280B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1084602A1 (en) | Tricyclic parp inhibitors | |
| WO2002044183A3 (en) | Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors | |
| TW200407322A (en) | Novel imidazopyridines as cyclin dependent kinase inhibitors | |
| HUP0500574A3 (en) | Acridone inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| IL181700A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
| SG145695A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| SG145700A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| ZA200710332B (en) | Bicyclic derivatives as modulators of ion channels | |
| HK1093064A1 (en) | Thienopyrimidine derivatives as potassium channel inhibitors | |
| MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
| ZA200706029B (en) | Tricyclic &-opioid domulators | |
| MXPA03008045A (es) | Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv. | |
| HUP0501182A3 (en) | Aza spiro alkane derivatives as inhibitors of metallproteases and pharmaceutical compositions containing them | |
| HUP0203288A3 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use | |
| AU2003226724A8 (en) | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands | |
| HUP0203245A3 (en) | Imidazopyridine derivatives as phosphodiesterase vii inhibitors and pharmaceutical compositions containing them | |
| EP1244452A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
| MY136840A (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
| MXPA05012953A (es) | Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos. | |
| PL2185561T3 (pl) | Pochodne 1,2,3,4-tetrahydropirolo(1,2-a)pirazyno-6-karboksamidów i 2,3,4,5-tetrahydropirolo(1,2-a)-diazepino-7-karboksamidów, ich wytwarzanie i zastosowanie terapeutyczne | |
| WO2002011732A8 (en) | Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists | |
| MX2007007627A (es) | Moduladores delta-opioides triciclicos. | |
| HUP0301173A3 (en) | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme | |
| HUP0400546A3 (en) | Tricyclic derivatives of indole with antiangiogenic activity and pharmaceutical compositions containing them |